Research into MPDL3280A for the Treatment of Lung Cancer

June 5, 2014
David Spigel, MD

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.

<<<

Back to "Immunotherapy News from ASCO"